Akeega has been approved for use in patients with BRCA2-mutated prostate cancer, specifically those with metastatic castration-sensitive disease. The approval is for a combination regimen, with some outlets specifying the inclusion of niraparib, abiraterone acetate, and prednisone. The exact scope of the approval may vary, with some reports indicating it is for metastatic hormone-sensitive prostate cancer.